We assessed the effects of candesartan in the 274 patients with hemorrhagic stroke , using the trial 's 2 coprimary effect variables : the composite vascular end point of vascular death , stroke or myocardial infarction , and functional outcome at 6 months , according to the modified Rankin Scale .